Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5–17 years in the United States: a cohort study

Rachel P. Ogilvie; J. Bradley Layton; Patricia C. Lloyd; Yixin Jiao; Djeneba Audrey Djibo; Hui Lee Wong; Joann F. Gruber; Ron Parambi; Jie Deng; Michael Miller; Jennifer Song; Lisa B. Weatherby; Lauren Peetluk; An‐Chi Lo; Kathryn Matuska; Michael Wernecke; Christine Bui; Tainya C. Clarke; Sylvia Cho; Elizabeth Bell; Grace Meijuan Yang; Kandace L. Amend; Richard A. Forshee; Steven A. Anderson; Cheryl N. McMahill‐Walraven; Yoganand Chillarige; Mary S. Anthony; John D. Seeger; Azadeh Shoaibi

doi:10.1186/s12887-024-04756-5

Abstract

COVID-19 vaccines are authorized for use in children in the United States; real-world assessment of vaccine effectiveness in children is needed. This study's objective was to estimate the effectiveness of receiving a complete primary series of monovalent BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in US children.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ogilvie et al. (2024) studied this question.

synapsesocial.com/papers/68e6d6b8b6db64358765358f https://doi.org/10.1186/s12887-024-04756-5

View Full Paper

Ask AI

Bookmark

Share

Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5–17 years in the United States: a cohort study

Abstract

Discussion

Cite This Study

Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5–17 years in the United States: a cohort study

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from BMC Pediatrics

Keep reading

More related papers

More from BMC Pediatrics